Dipeptidyl Peptidase 4 Inhibitor [EPC]

32611 reported adverse events

Drugs of this class: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE SITAGLIPTIN LINAGLIPTIN LINAGLIPTIN AND METFORMIN HYDROCHLORIDE EMPAGLIFLOZIN AND LINAGLIPTIN EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE SITAGLIPTIN HYDROCHLORIDE ORAL

These side effects are most commonly reported by patients taking drugs of the Dipeptidyl Peptidase 4 Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 2023
1 NAUSEA 1937
2 BLOOD GLUCOSE INCREASED 1872
3 ACUTE KIDNEY INJURY 1802
4 FATIGUE 1705
5 DYSPNOEA 1620
6 VOMITING 1565
7 OFF LABEL USE 1448
8 DIZZINESS 1447
9 DRUG INEFFECTIVE 1202
See all common reactions for Dipeptidyl Peptidase 4 Inhibitor [EPC]

Drugs of the Dipeptidyl Peptidase 4 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARDIOSPASM 396 0.7097
1 IMMUNISATION 258 0.5945
2 PALMOPLANTAR KERATODERMA 391 0.5393
3 ATRIAL TACHYCARDIA 398 0.1893
4 PRURITUS GENITAL 405 0.1718
5 CAROTID ARTERY OCCLUSION 403 0.1104
6 SLEEP TERROR 390 0.0925
7 TENSION HEADACHE 394 0.0915
8 EUGLYCAEMIC DIABETIC KETOACIDOSIS 317 0.0767
9 PRODUCT MONITORING ERROR 98 0.0678
See all enriched reactions for Dipeptidyl Peptidase 4 Inhibitor [EPC]